Ultrasensitive serum interferon-α quantification during SLE remission identifies patients at risk for relapse.
Fiche publication
Date publication
septembre 2019
Journal
Annals of the rheumatic diseases
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DEVILLIERS Hervé
Tous les auteurs :
Mathian A, Mouries-Martin S, Dorgham K, Devilliers H, Yssel H, Garrido Castillo L, Cohen-Aubart F, Haroche J, Hié M, Pineton de Chambrun M, Miyara M, Pha M, Rozenberg F, Gorochov G, Amoura Z
Lien Pubmed
Résumé
Maintenance of remission has become central in the management of systemic lupus erythematosus (SLE). The importance of interferon-alpha (IFN-α) in the pathogenesis of SLE notwithstanding, its expression in remission has been poorly studied as yet. To study its expression in remission and its prognostic value in the prediction of a disease relapse, serum IFN-α levels were determined using an ultrasensitive single-molecule array digital immunoassay which enables the measurement of cytokines at physiological concentrations.
Mots clés
biomarker, flare, interferon-alpha, low disease activity, relapse, remission, systemic lupus erythematosus
Référence
Ann. Rheum. Dis.. 2019 Sep 30;: